Results 11 to 20 of about 1,651 (200)

Astatine-211-Towards In Vivo Stable Astatine-211 Labeled Radiopharmaceuticals and Their (Pre)Clinical Applications. [PDF]

Med Res Rev
ABSTRACTTargeted radioligand therapy has emerged as a promising treatment option for eradicating advanced cancer forms. α‐Emitters are considered particularly promising as they can obliterate (micro)‐metastases. The α‐emitter astatine‐211 (211At) has experienced increased interest due to its favorable decay properties.
Müller M, Pedersen NB, Shalgunov V, Jensen AI, Battisti UM, Herth MM.   +5 more
europepmc   +4 more sources

Pretargeted Alpha Therapy of Disseminated Cancer Combining Click Chemistry and Astatine-211 [PDF]

Pharmaceuticals, 2023
To enhance targeting efficacy in the radioimmunotherapy of disseminated cancer, several pretargeting strategies have been developed. In pretargeted radioimmunotherapy, the tumor is pretargeted with a modified monoclonal antibody that has an affinity for ...
Chiara Timperanza, Holger Jensen, Tom Bäck, Sture Lindegren, Emma Aneheim   +4 more
doaj   +2 more sources

Biodistributions, Myelosuppression, and Toxicities in Mice Treated with an Anti-CD45 Antibody Labeled with the α-Emitting Radionuclides Bismuth-213 or Astatine-211 [PDF]

, 2009
We previously investigated the potential of targeted radiotherapy using a bismuth-213- labeled anti-CD45 antibody to replace total body irradiation as conditioning for hematopoietic cell transplantation in a canine model.
Hirohisa Nakamae, D. Scott Wilbur, Donald K. Hamlin, Monica S. Thakar, Erlinda B. Santos, Darrell R. Fisher, Aimee L. Kenoyer, John M. Pagel, Oliver W. Press, Rainer Storb, Brenda M. Sandmaier   +10 more
openalex   +4 more sources

Surface Adsorption of the Alpha-Emitter Astatine-211 to Gold Nanoparticles Is Stable In Vivo and Potentially Useful in Radionuclide Therapy [PDF]

Journal of Nanotheranostics, 2021
Targeted α-therapy (TAT) can eradicate tumor metastases while limiting overall toxicity. One of the most promising α-particle emitters is astatine-211 (211At).
Emanuel Sporer, Christian B. M. Poulie, Sture Lindegren, Emma Aneheim, Holger Jensen, Tom Bäck, Paul J. Kempen, Andreas Kjaer, Matthias M. Herth, Andreas I. Jensen   +9 more
doaj   +2 more sources

Astatine-211-Labeled Gold Nanoparticles for Targeted Alpha-Particle Therapy via Intravenous Injection [PDF]

Pharmaceutics, 2022
Alpha-particle radiotherapy has gained considerable attention owing to its potent anti-cancer effect. 211At, with a relatively short half-life of 7.2 h, emits an alpha particle within a few cell diameters with high kinetic energy, which damages cancer ...
Xuhao Huang, Kazuko Kaneda-Nakashima, Yuichiro Kadonaga, Kazuya Kabayama, Atsushi Shimoyama, Kazuhiro Ooe, Hiroki Kato, Atsushi Toyoshima, Atsushi Shinohara, Hiromitsu Haba, Yang Wang, Koichi Fukase   +11 more
doaj   +2 more sources

Behaviour, use and safety aspects of astatine-211 solvated in chloroform after dry distillation recovery [PDF]

Scientific Reports
Targeted alpha therapy of disseminated cancer is an emerging technique where astatine-211 is one of the most promising candidate nuclides. Astatine-211 can be produced in medium energy cyclotrons by alpha particle bombardment of natural bismuth.
Emma Aneheim, Ellinor Hansson, Chiara Timperanza, Holger Jensen, Sture Lindegren   +4 more
doaj   +2 more sources

Solving the limited availability of Astatine-211 from a European perspective: from production to the end user [PDF]

EJNMMI Radiopharmacy and Chemistry
Background Astatine-211, 211At, has long been a candidate for Targeted Alpha Therapy, TAT. However, over time, hurdles in the development of chemistry, the establishment of radiopharmacies, and the demonstration of its potential in clinical trials have ...
Sture Lindegren, Holger Jensen, Hans Van de Maele, Renata Mikolajczak, Haingo Rabarijaona, Emma Aneheim   +5 more
doaj   +2 more sources

THE INDUCTION OF TUMORS IN THE RAT BY ASTATINE-211 [PDF]

Radiation Research, 1958
Exposure of rats to sublethal amounts of At/sup 211/ results in the early appearance of large numbers of mammary tumors, many of them malignant, and in the production of an altered functional state simulating menopause. It is evident that the tumor induction is not yet tested for its association with radiation exposure separately from the endocrine ...
Patricia W. Durbin, C. Willet Asling, Muriel E. Johnston, Marshall W. Parrott   +3 more
openalex   +6 more sources

Brain intratumoural astatine-211 radiotherapy targeting syndecan-1 leads to durable glioblastoma remission and immune memory in female miceResearch in context [PDF]

EBioMedicine
Summary: Background: Glioblastoma (GB), the most aggressive brain cancer, remains a critical clinical challenge due to its resistance to conventional treatments. Here, we introduce a locoregional targeted-α-therapy (TAT) with the rat monoclonal antibody
Loris Roncali, Séverine Marionneau-Lambot, Charlotte Roy, Romain Eychenne, Sébastien Gouard, Sylvie Avril, Nicolas Chouin, Jérémie Riou, Mathilde Allard, Audrey Rousseau, François Guérard, François Hindré, Michel Chérel, Emmanuel Garcion   +13 more
doaj   +2 more sources

Development of LAT1-Selective Nuclear Medicine Therapeutics Using Astatine-211. [PDF]

Int J Mol Sci
We investigated nuclear medicine therapeutics targeting the L-type amino acid transporter 1 (LAT1). We previously reported that a nuclear medicine therapeutic drug using astatine 211 (211At), an alpha-emitting nuclide that can be produced in an accelerator and targets LAT1 as a molecular target, is effective.
Kaneda-Nakashima K, Shirakami Y, Hisada K, Feng S, Kadonaga Y, Ooe K, Watabe T, Manabe Y, Shimoyama A, Murakami M, Toyoshima A, Haba H, Kanai Y, Fukase K.   +13 more
europepmc   +3 more sources